A nationwide prospective cohort study on safety of the 17D-204 yellow fever vaccine during a vaccine shortage in Japan.

Autor:	Miyazato, Yusuke, Terada, Mari, Ujiie, Mugen, Saito, Sho, Moriya, Akinari, Ando, Masao, Ohmagari, Norio
Předmět:	YELLOW fever TONSILLITIS COHORT analysis
Zdroj:	Journal of Travel Medicine; Mar2023, Vol. 30 Issue 2, p1-4, 4p
Abstrakt:	He was diagnosed with adhesive bowel obstruction, which was treated conservatively and the patient recovered
M/22	Tonsillitis	29	Serious	Related/cannot be ruled out	The subject with no previous medical history presented with mild sore throat and fever appearing on Day 6 post-vaccination, which was judged to have been caused by the vaccination by the site physician. No adverse event occurred to the baby

ht Onset time is counted from vaccination day (vaccination = Day 0). He was diagnosed with adhesive bowel obstruction, which was treated conservatively and the patient recovered M/22 Tonsillitis 29 Serious Related/cannot be ruled out The subject with no previous medical history presented with mild sore throat and fever appearing on Day 6 post-vaccination, which was judged to have been caused by the vaccination by the site physician. On 24 July 2017, Sanofi Pasteur, yellow fever vaccine (YF-VAX) manufacturer, announced a vaccine shortage caused by manufacturing delays.[1] Consequently, some countries were forced to take compensatory measures. [Extracted from the article] Databáze: Complementary Index Externí odkaz: